Remdesivir has marginal benefit for moderate COVID-19 patients: Gilead study
Moderately ill COVID-19 patients saw their condition improve after a 5-day course of Gilead Sciences Inc’s remdesivir, but a 10-day course did not show a benefit and the drug did…